NABI Insider Trading Activity and SEC Form 4 Filings
NABI insider trading summary
No open-market insider purchases or sales of Nabi Biopharmaceuticals (NABI) have been reported on SEC Form 4 in the past 12 months.
Latest NABI insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Apr 5, 2012 | Paul D. Kessler | SVP Clinical, Med. & Reg.; CMO | Sell | $10K (5,167 @ $1.90) |
| May 16, 2011 | Paul D. Kessler | SVP Clinical, Med. & Reg.; CMO | Sell | $27K (4,876 @ $5.48) |
| May 16, 2011 | Paul D. Kessler | SVP Clinical, Med. & Reg.; CMO | Sell | $41K (7,500 @ $5.53) |
| Apr 5, 2011 | Paul D. Kessler | SVP Clinical, Med. & Reg.; CMO | Sell | $49K (8,596 @ $5.76) |
| Apr 5, 2011 | Raafat E F Fahim | President, CEO and CFO | Sell | $76K (13,283 @ $5.76) |
| Apr 1, 2011 | Matthew W. Kalnik | SVP Strategic Plan. & Bus. Ops | Sell | $37K (6,300 @ $5.80) |
| Mar 15, 2011 | Jason Aryeh | Director | Sell | $29K (4,900 @ $5.87) |
| Mar 14, 2011 | Jason Aryeh | Director | Sell | $6K (1,000 @ $5.86) |
| Mar 14, 2011 | Jason Aryeh | Director | Sell | $14K (2,400 @ $5.82) |
| Mar 11, 2011 | Jason Aryeh | Director | Sell | $57K (9,900 @ $5.75) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.